AKTX Akari Therapeutics Plc
Distress ·
Akari Therapeutics says its quarterly report for the period ended March 31, 2026 will be late, partly because of work on an upcoming public offering. It also expects a material non-cash impairment charge, and its March 2026 annual report carried a going-concern paragraph.
Nasdaq told Akari Therapeutics on November 24, 2025 that its American Depositary Shares had closed below $1.00 for 30 consecutive business days. The company has until May 25, 2026 to regain compliance, and its 2024 annual report carries a going-concern warning.
The company is still finishing the accounting for its November 14, 2024 business combination. It expects to file within the 15-day extension.
About 99% of shares present voted in support. Akari targets a close on November 13, 2024 and expects the deal to fix its Nasdaq equity deficiency.
Akari Therapeutics Plc is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel proprietary payloads. Its lead payload, PH1, modulates the spliceosome, a complex cellular machinery that converts pre-RNA into spliced RNA, and the company says PH1 causes cancer cell death and generates neoantigen proteins that activate innate and adaptive immune systems. The company says PH1 has been demonstrated to be active against metastatic prostate cancer cells driven by AR-v7. Its lead ADC candidate, AKTX-101, targets the Trop-2 receptor on cancer cells and uses a proprietary linker to deliver PH1 directly into the tumor. The company has initiated IND-enabling studies for AKTX-101, with a goal of starting a first-in-human Phase 1 trial by late 2026 or early 2027. It is also advancing AKTX-102, an ADC against CEACAM5, a target the company says is relevant in pancreatic, colon, stomach, esophageal and lung cancers. The company notes that the PH1 platform can generate ADC candidates against different cancer antigen targets.
| Product or program | What it is | Stage |
|---|---|---|
| PH1 payload | Novel RNA splicing modulating payload for ADC candidates | |
| AKTX-101 | Trop-2 targeted ADC carrying the PH1 payload | IND-enabling studies; Phase 1 targeted for late 2026 or early 2027 |
| AKTX-102 | CEACAM5 targeted ADC |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.8 million | $7.0 million |
| Net income (loss) | -$17.3 million | -$19.8 million |
| Cash from operations | -$10.6 million | -$12.6 million |
| Cash and equivalents | $5.2 million | $0 |
Opinion Negative view
Akari had $7.7 million at June 30, 2026. Our arithmetic gives about nine months, the company says December 2026, and its lead drug is not yet in the clinic.
Our latest story on this, dated May 18, 2026: "Akari Therapeutics files NT 10-Q, cites public offering work and expected impairment". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 18, 2026: "Akari Therapeutics files NT 10-Q, cites public offering work and expected impairment". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Nov 26, 2025: "Akari Therapeutics gets Nasdaq minimum bid price deficiency notice, has until May 25, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 31, 2025: "Akari Therapeutics delays 2024 annual report over merger accounting". The story links the filing or release it is based on. Read the story.
Akari Therapeutics Plc trades under the ticker AKTX on NASDAQ.
Akari Therapeutics Plc is listed on NASDAQ.
The SEC Central Index Key (CIK) for Akari Therapeutics Plc is 1541157. Its filings are on SEC EDGAR.
155,758,529,533 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Akari Therapeutics Plc under United States.
Our directory classifies Akari Therapeutics Plc as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Akari Therapeutics Plc is US00972G4055.
aibio.space lists Akari Therapeutics Plc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as X0.
Akari Therapeutics Plc is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel proprietary payloads. Its lead payload, PH1, modulates the spliceosome, a complex cellular machinery that converts pre-RNA into spliced RNA, and the company says PH1 causes cancer cell death and generates neoantigen proteins that activate innate and adaptive immune systems.
PH1 payload: Novel RNA splicing modulating payload for ADC candidates Stage: not stated in text.
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,7.01,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.01,3.01,3.02,5.02,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.07,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio